NSCLC patients

ASCO 2023:Kelun Pharma’s SKB264 shows early signs of potential in NSCLC patients

ASCO 2023:Kelun Pharma’s SKB264 shows early signs of potential in NSCLC patients

SG Tylor

ABSTRACT NUMBER – 9114 SKB264 is an innovative anti-TROP2 ADC that specifically targets a poor prognosis marker found in 70% ...